The FDA Center for Biologics Evaluation and Research (CBER) is inviting biologics facilities to participate in its Regulatory Site Visit Training Program, which is intended to allow CBER staff to directly observe routine biologics manufacturing practices. Interested parties should contact CBER by February 21.